Myelofibrosis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{Myelofibrosis}} | {{Myelofibrosis}} | ||
{{CMG}} | {{CMG}}{{AE}}{{Sab}} | ||
==Overview== | ==Overview== | ||
| Line 11: | Line 11: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category: | [[Category:Medicine]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Oncology]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | |||
[[Category:Up-To-Date]] | |||
Latest revision as of 22:50, 29 July 2020
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis secondary prevention |
|
Risk calculators and risk factors for Myelofibrosis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]
Overview
There are no established measures for the secondary prevention of myelofibrosis.
Secondary Prevention
There are no established measures for the secondary prevention of myelofibrosis.